[1] B. CAMPBELL. Beta-lactamase activity of purified and partially characterized human renal dipeptidase.[J]. The Journal of Biological Chemistry, 1984, 105 1: 14586-14590. DOI:
10.1016/s0021-9258(17)42642-1[2] F M KAHAN. Thienamycin: development of imipenen-cilastatin.[J]. Journal of Antimicrobial Chemotherapy, 1983, 12 Suppl D: 1-35. DOI:
10.1093/jac/12.suppl_d.1[3] S KEYNAN. The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA.[J]. Antimicrobial Agents and Chemotherapy, 1995, 39 7: 1629-1631. DOI:
10.1128/aac.39.7.1629[4] BLANCA HUMANES. Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.[J]. BioMed Research International, 2015: 704382. DOI:
10.1155/2015/704382[5] P J PETERSEN. In vitro and in vivo activities of LJC10,627, a new carbapenem with stability to dehydropeptidase I.[J]. Antimicrobial Agents and Chemotherapy, 1991, 35 1: 203-207. DOI:
10.1128/aac.35.1.203